4-(氨甲基)苯并[B]噻吩 | 864264-04-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 4-(氨甲基)苯并[B]噻吩
• 英文名称: 4-benzothiophenemethanamine
• 英文别名: 4-(Aminomethyl)benzo[b]thiophene；1-benzothiophen-4-ylmethanamine
• CAS: 864264-04-0
• 化学式: C₉H₉NS
• 分子量: 163.243
• InChiKey: TZFMFHJVMMZUJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  54.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(氨甲基)苯并[B]噻吩 在 sodium tetrahydroborate 作用下， 以 甲醇 、 苯 为溶剂， 反应 0.33h， 生成 Benzothiophen-4-ylmethyl-cinnamyl-amine
  参考文献：
  名称：

  Synthesis and structure-activity relationships of naftifine-related allylamine antimycotics

  摘要：

  Naftifine (1) is the first representative of the new antifungal allylamine derivatives. Its biological activity is strictly bound to specific structural requirements that are unrelated to those of known antifungals. A tertiary allylamine function seems to be a prerequisite for activity against fungi. By systematic variation of the individual structural elements in 1, detailed structure-activity relationships are defined in which the phenyl ring is the structural feature permitting the widest variations. Versatile synthetic routes to allylamine derivatives and comparative biological data are presented.

  DOI：

  10.1021/jm00151a019
• 作为产物：
  描述：

  Lithium aluminium hydride 、 苯并[b]噻吩-4-甲腈 、 水 、 sodium hydroxide 在 4-(氨甲基)苯并[B]噻吩 、 甲醇 、 amine 、 氨 作用下， 以 四氢呋喃 为溶剂， 反应 17.0h， 以to give the title compound (0.57 g, 93%)的产率得到4-(氨甲基)苯并[B]噻吩
  参考文献：
  名称：

  6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist

  摘要：

  本发明提供了公式I的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环作为选择性5-HT2C受体激动剂，用于治疗5-HT2C相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6为—S—R14；其他取代基如规范中所定义。

  公开号：

  US20120028961A1
• 作为试剂：
  描述：

  Lithium aluminium hydride 、 苯并[b]噻吩-4-甲腈 、 水 、 sodium hydroxide 在 4-(氨甲基)苯并[B]噻吩 、 甲醇 、 amine 、 氨 作用下， 以 四氢呋喃 为溶剂， 反应 17.0h， 以to give the title compound (0.57 g, 93%)的产率得到4-(氨甲基)苯并[B]噻吩
  参考文献：
  名称：

  6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS

  摘要：

  本发明提供了式I的6-取代的2,3,4,5-四氢-1H-苯并氮烯作为选择性5-HT2C受体激动剂，用于治疗5-HT2C相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6为-C≡C-R10，-O-R12，-S-R14或-NR24R25；其他取代基如规范中所定义。

  公开号：

  US20090099155A1

文献信息

• Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT2A receptor antagonists/inverse agonists
  作者：Mingxu Ma、Yifei Yang、Guangying Du、Yusen Dai、Xiaoyin Zhu、Wenyan Wang、Hengwei Xu、Jianzhao Zhang、Lixia Zheng、Fangxia Zou、Huijie Yang、Bin Liu、Wanhui Liu、Liang Ye、Rui Zhang、Jingwei Tian

  DOI：10.1016/j.ejmech.2022.114246

  日期：2022.4

  series of novel pimavanserin derivatives (7–1∼7–37) were designed and synthesized. The biological activities were evaluated by cell assays and compound 7–16 exhibited 50-fold higher 5-HT2A receptor antagonist activity (IC50 = 0.54 vs 27.3 nM) and 23-fold higher inverse agonist activity (IC50 = 2.1 vs 50 nM) than pimavanserin. Moreover, 7–16 showed increased potency window between the 5-HT2A and hERG

  Pimavanserin是FDA于2016年批准的选择性5-HT 2A受体拮抗剂和反向激动剂，用于治疗帕金森病精神病（PDP）患者。但匹马万色林具有潜在风险，会增加老年患者的死亡率，也会增加患者 QT 间期延长的风险。因此，迫切需要寻找高效、低毒的新药。基于匹马范色林的对接研究，设计合成了一系列新型匹马范色林衍生物（ 7-1∼7-37 ）。通过细胞试验评估了生物活性，化合物7 – 16的 5-HT 表现出高 50 倍2A受体拮抗剂活性（IC 50  = 0.54 vs 27.3 nM）和反向激动剂活性（IC 50  = 2.1 vs 50 nM）是匹马万色林的 23 倍。此外，7 - 16显示 5-HT2A 和 hERG 活性之间的效力窗口比匹马万色林增加。此外，化合物7-16表现出优异的体外和体内药代动力学，体内功能活性提高了4倍，并且具有良好的安全性。因此，化合物7 – 16代表了一种
• IMINOPYRIDINE DERIVATIVE AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2077262A1

  公开（公告）日：2009-07-08

  Provided are an iminopyridine derivative having a selective α1D adrenergic receptor antagonistic action and useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like, and a screening method for a compound having an α1D adrenergic receptor antagonistic action. An α1D adrenergic receptor antagonist containing a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof, and a method of screening for an agent having an α1D adrenergic receptor antagonistic action for the prophylaxis or treatment of a lower urinary tract disease, which includes measuring the bladder smooth muscle tension of rats with bladder outlet obstruction.

  提供了一种具有选择性α1D肾上腺素能受体拮抗作用的咪唑吡啶衍生物，可用作预防或治疗下尿路疾病等药物，以及一种筛选具有α1D肾上腺素能受体拮抗作用的化合物的方法。该α1D肾上腺素能受体拮抗剂包含由下式表示的化合物或其盐：其中，每个符号如规范中所定义。该方法包括测量具有膀胱出口梗阻的大鼠膀胱平滑肌张力的药物，用于预防或治疗下尿路疾病的α1D肾上腺素能受体拮抗剂的筛选方法。
• Iminopyridine Derivative and Use Thereof
  申请人：Yoshida Masato

  公开号：US20100016315A1

  公开（公告）日：2010-01-21

  Provided are an iminopyridine derivative having a selective α 1D adrenergic receptor antagonistic action and useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like, and a screening method for a compound having an α 1D adrenergic receptor antagonistic action. An α 1D adrenergic receptor antagonist containing a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof, and a method of screening for an agent having an α 1D adrenergic receptor antagonistic action for the prophylaxis or treatment of a lower urinary tract disease, which includes measuring the bladder smooth muscle tension of rats with bladder outlet obstruction.

  提供了一种具有选择性α1D肾上腺素受体拮抗作用的咪唑吡啶衍生物，可用作预防或治疗下尿路疾病等药物，以及一种筛选具有α1D肾上腺素受体拮抗作用的化合物的方法。一种含有以下式子所表示的化合物或其盐的α1D肾上腺素受体拮抗剂：其中每个符号如规范中所定义，以及一种筛选用于预防或治疗下尿路疾病的具有α1D肾上腺素受体拮抗作用的药物的方法，该方法包括测量具有膀胱出口梗阻的大鼠膀胱平滑肌张力。
• 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist
  申请人：ALLEN JOHN GORDON

  公开号：US20120028961A1

  公开（公告）日：2012-02-02

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R 6 is —S—R 14 ; and other substituents are as defined in the specification.

  本发明提供了公式I的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环作为选择性5-HT2C受体激动剂，用于治疗5-HT2C相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6为—S—R14；其他取代基如规范中所定义。
• 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
  申请人：Eli Lilly and Company

  公开号：US08022062B2

  公开（公告）日：2011-09-20

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —C≡C—R10, —O—R12, —S—R14, or —NR24R25; and other substituents are as defined in the specification.

  本发明提供了式I的6-取代2,3,4,5-四氢-1H-苯并[d]氮杂环化合物，作为选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6是—C≡C—R10，—O—R12，—S—R14或—NR24R25; 其他取代基如规范中定义。